On Monday, Illumina reduced its yearly outlook and announced plans to save $100 million after China declared a ban on importing its genetic sequencing devices.
Illumina, Inc. announced that its Non-GAAP Diluted EPS for Fiscal Year 2025 is expected to be around $4.50. On March 10, 2025, the company responded to a notice from the China Ministry of Commerce stating that it cannot export sequencing instruments to China. Illumina acknowledges this decision and will adhere to all relevant laws and regulations in its operations.
Illumina, Inc. (NASDAQ: ILMN), a top company in DNA sequencing and array-based technologies, has been recognized for the sixth consecutive year in the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index. For the fourth year running, it has also been included in the Sustainability Yearbook. Illumina achieved a score in the top 15% of the Best-in-Class World Index and was the highest-scoring U.S. company in the Life Sciences Tools & Services Sector.
In February, Illumina was added to China's list of "unreliable entities."
On Tuesday, China declared a ban on importing genetic sequencers from the American medical equipment company Illumina. This announcement came just moments after U.S. President Donald Trump implemented an extra 10% tariff on Chinese products.
Illumina, Inc. (NASDAQ:ILMN) will hold an investor session at the AGBT Conference on February 25, 2025, at 11:00 AM ET. The company representatives include Salli Schwartz, Jacob Thaysen, Steve Barnard, and Ankur Dhingra. Various conference call participants from different financial firms are also present, and Salli Schwartz begins by thanking everyone for their patience.
Illumina is working together with Broad Clinical Labs to establish a standard for scalable single-cell research. This partnership aims to speed up discoveries in fields like disease modeling and drug development.
Longtime partners are combining their advanced workflows and top CRISPRPerturb-seq technologies to establish a benchmark for single-cell research, aiming to create a 5 billion single-cell atlas in three years. On February 21, 2025, Illumina, Inc., a leader in next-generation sequencing, announced a partnership with Broad Clinical Labs to enhance and expand single-cell projects using innovative tools and processes. This collaboration will help speed up the progress of scalable single-cell studies.
The Broad Institute is partnering on a major project that utilizes Illumina's latest spatial technology. At the AGBT event, clients will showcase data highlighting exceptional scale and sensitivity in studies related to pulmonary fibrosis, prostate cancer, and 3D models of mouse brains. Illumina is also enhancing its software offerings to analyze various types of data through its Connected Multiomics platform.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.